Global Tissue Banking Market Overview
Tissue Banking Market size was valued at USD 1.36 billion in 2022. The tissue banking market industry is projected to grow from USD 1.46 billion in 2023 to USD 3.42 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.5% during the forecast period (2024 - 2032).
The increased incidence of cardiovascular disease, cancer, diabetes is driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Tissue Banking Market Trends
- Increasing prevalence of cardiovascular, cancer, and diabetes disease boosts the market growth.
The increasing prevalence of chronic diseases such as cancer, heart disease, and diabetes disease majorly impact all over the world as well as raises the demand for advanced treatment alternatives for the treatment of chronic disease. As rising risk of chronic disease seems the best treatment alternative for tissue banking. In addition, as per the American Cancer Society, approximately 1.9 million new cases of cancer were diagnosed in the US. Furthermore, heart disease is considered as the leading cause of death for women and men. One person dies every 33 seconds in the US from cardiovascular disease.
Approximately 4,66,566 people suffered from heart disease in the US. Heart disease costs the US around USD 239.9 billion every year from 2018 to 2019.
Thus, the rising prevalence of heart disease cancer, and diabetes is increasing the demand for tissue banking so key players are keenly interested in the research and development activity for new product development which propels the growth of tissue banking.
Tissue Banking Market Segment Insights
Tissue Banking Type Insights
The Tissue Banking Market segmentation, based on type, includes media and consumable, cryopreservation equipment, thawing equipment, quality control equipment, and others. The media and consumable segment are to hold the majority share in 2022 in the Tissue Banking Market revenue due to the launch of new products in the market.
For instance, in May 2022, the major US report of selective fertility preservation outcomes to date found that 70% of women who froze eggs when they were youthful than 38 as well as defrosted at least 20 eggs at a future date.
Tissue Banking Tissue Type Insights
The Tissue Banking Market segmentation is based on tissue types that include heart valve, cornea, bone, skin, brain & spinal cord, and others. The heart valve segment has dominated the market in 2022 due to the increasing prevalence of heart disease across the globe.
For instance: As per the British Heart Foundation in 2023, around 200 million population suffer from coronary heart disease. Globally 80 million and 110 million men had coronary heart disease.
Tissue Banking Application Insights
The Tissue Banking Market segmentation is based on applications that include therapeutics, medical research, and others. The therapeutics segment has dominated the market in 2022 due to the development of novel therapeutics for the treatment of various chronic diseases as well as growing research and development activity for the new products.
Figure 2: TISSUE BANKING MARKET, BY APPLICATION, 2024 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Tissue Banking Regional Insights
By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America accounted for the largest market share in 2022 owing to the North Americas is expected to command the largest market share due to the increasing tendency of egg frozen in the US, availability of advance technology, increasing healthcare infrastructure, developed economic condition boos the growth of tissue banking in the North America region.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: TISSUE BANKING MARKET, BY REGION, 2024 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe tissue banking market is expected to account for the second-largest market share due to the growth of the market are increasing technological development and product innovation, rising research and development activity, increasing occurrence of life threating disease such as heart disease, cancer, and others. Furthermore, increasing numbers of organ donors across the region is driving the growth of tissue banking. Furthermore, the Germany tissue banking market held the largest market share in 2022 and UK tissue banking market is the fastest growing market in the Europe region.
The Asia-Pacific tissue banking market is expected to grow at a CAGR of 6.90% from 2019 to 2032. This is due to increasing investment by foreign companies, huge chronic disease population, increasing penetration of frozen eggs are driving the growth of tissue banking in the Asia-pacific region.
Moreover, Japan tissue banking market held the largest market share in 2022 and India tissue banking market is the fastest growing market in the Asia-Pacific region.
The Rest of the World includes the Middle East, Africa, and Latin America. Latin America holds the major market share in the middle east and Africa region due to the region’s growth is attributed to a growing use of tissue banking, rising awareness about the organ donation for saving other life, growing new technological development and advance medical facility across the region are boost the growth of tissue banking in region.
Tissue Banking Key Market Players & Competitive Insights
The Tissue Banking Market is distinguished by the presence of numerous global, regional, and local players catering to the increasing need for products in the emerging threat. Moreover, factors such as the increasing threat of bioterrorism, growing awareness of the potential for pandemics, and advances in biotechnology have made it possible to develop new and more effective tissue banking products. Moreover, the numerous pipeline products are responsible for the intense competition and huge opportunities during the forecast period.
Additionally, manufacturers are entering into strategic alliances such as acquisitions, mergers, collaborations, product launches, and product approvals. These strategic alliances are creating intense rivalry for the newcomer as well as for the existing brand.
Thermo Fisher Scientific Inc specializes in various biotechnology products such as analytical instruments, laboratory supply chain programs and e-commerce, laboratory equipment, lab services, specialty diagnostics, and others.
The company helps its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to the market, and increase the productivity of the laboratory. It has five premier brands, namely, Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services through which it offers an unmatched combination of innovative technologies, purchasing convenience, and comprehensive services.
Key Companies in the Tissue banking Market Include.
- Thermo Fisher Scientific Inc. (US)
- Sigma-Aldrich Co. (US)
- BioLifeSolutions (US)
- Lifeline Scientific (US)
- BioCision, Cesca Therapeutics, Inc. (US)
- core dynamics GmbH (US)
- Custom Biogenic Systems (US)
- Atlanta Biologics Pvt. Ltd. (US)
- Taylor-Wharton (US)
- Panasonic Holdings Corporation (Japan)
Tissue Banking Industry Developments
Thermo Fisher Scientific Inc. (US)
In 2024, Thermo Fisher Scientific continues to drive innovation in tissue preservation and regenerative medicine. The company has made significant progress with its 3D cell culture technologies, such as organoids, which replicate tissue structures more effectively. These advancements enable groundbreaking research in areas like cancer, neurobiology, and stem cell therapy by providing better in vitro models.
Furthermore, Thermo Fisher’s specialized reagents and imaging systems have become pivotal in improving tissue banking protocols and ensuring enhanced cellular viability for research and therapeutic purposes​.
Sigma-Aldrich Co. (US)
As part of Merck KGaA, Sigma-Aldrich remains a leader in bioreagent development for tissue banking. The company’s latest innovations include high-quality cryoprotectants, culture media, and reagents tailored for cell and tissue storage. These products are critical for maintaining tissue viability during long-term preservation, supporting the growing applications of regenerative medicine in both clinical and research environments.
In 2024, Sigma-Aldrich has also expanded its biopreservation solutions to meet the increasing demand for advanced tissue storage technologies​.
BioLife Solutions (US)
BioLife Solutions has solidified its position as a pioneer in biopreservation media with its flagship products, CryoStor® and HypoThermosol®. These solutions are designed to maximize post-thaw cell and tissue viability, which is crucial for tissue banks and regenerative therapies.
In 2024, the company has further expanded its portfolio to include automated biopreservation and storage systems, offering scalable and secure solutions for tissue and cell preservation. This expansion underscores BioLife’s commitment to supporting cutting-edge tissue banking infrastructure globally​.
Lifeline Scientific (US)
Known for its LifePort® organ preservation systems, Lifeline Scientific continues to innovate in the field of organ and tissue storage. The company’s technologies focus on maintaining tissue viability during transportation and long-term storage, reducing ischemic damage, and enhancing transplant outcomes.
Recent advancements include improved tissue storage solutions tailored for research and transplantation applications. Lifeline’s efforts in 2024 aim to bridge the gap between tissue banking and regenerative medicine​.
Tissue Banking Market Segmentation
Tissue Banking Type Outlook
- Media and Consumable
- Cryopreservation Equipment
- Thawing Equipment
- Quality Control Equipment
- Others
Tissue Banking Tissue Type Outlook
- Heart Valve
- Cornea
- Bone
- Skin
- Brain & Spinal Cord
- Others
Tissue Banking Application Outlook
- Therapeutics
- Medical Research
- Others
Tissue Banking Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Report Attribute/Metric |
Details |
 Market Size 2022 |
USD 1.36 billion |
 Market Size 2023 |
USD 1.46 billion |
Market Size 2032 |
USD 3.42 billion |
Compound Annual Growth Rate (CAGR) |
8.5% (2024- 2032) |
Base Year |
2023 |
Forecast Period |
2024- 2032 |
Historical Data |
2019 & 2020,2021 |
Forecast Units |
Value (USD Billion) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Type, Tissue Type, Application, and Region |
Geographies Covered |
North America, Europe, Asia Pacific, and Rest of the World |
Countries Covered |
The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
Key Companies Profiled |
Thermo Fisher Scientific Inc. (US), Sigma-Aldrich Co. (US), BioLifeSolutions (US), Lifeline Scientific (US), BioCision, Cesca Therapeutics, Inc. (US),core dynamics GmbH (US), Custom Biogenic Systems (US),Atlanta Biologics Pvt. Ltd. (US), Taylor-Wharton (US), Panasonic Holdings Corporation (Japan), and among others and others |
Key Market Opportunities |
·      Increasing awareness about the tissue banking |
Key Market Dynamics |
·      Increasing prevalence of cardiovascular disease |
Tissue Banking Market Highlights:
Frequently Asked Questions (FAQ) :
The Tissue Banking Market is anticipated to reach USD 1.36 billion by at a CAGR of 8.5% during the forecast period of 2024 to 2032.
The US tissue banking market is anticipated to reach USD 0.67 billion in 2023 at a CAGR of 8.0% during the forecast period of 2024 - 2032.
The Tissue Banking Market is expected to register a CAGR of 8.5% during the forecast period of 2024 - 2032.
The North America tissue banking market accounted for USD 0.71 billion in 2023 and is expected to exhibit a 7.9% CAGR during the study period.
Thermo Fisher Scientific Inc (US), Sigma-Aldrich Co. (US), BioLifeSolutions (US), Lifeline Scientific (US), BioCision, Cesca Therapeutics, Inc. (US),core dynamics GmbH (US), Custom Biogenic Systems (US),Atlanta Biologics Pvt. Ltd. (US), Taylor-Wharton (US), Panasonic Holdings Corporation (Japan) and among others
The media and consumable segment held the majority share in 2022 contributing to around 43.2% with respect to the Tissue Banking Market.
The heart valve segment held the majority share in 2022 contributing to around 47.4% with respect to the Tissue Banking Market.
The therapeutics segment held the majority share in 2022 contributing to around 81.9% with respect to the Tissue Banking Market.